Genetic pharmacology: progresses in siRNA delivery and therapeutic applications - Archive ouverte HAL Access content directly
Journal Articles Gene Therapy Year : 2017

Genetic pharmacology: progresses in siRNA delivery and therapeutic applications

(1) , (1) , (1) , (1)
1

Abstract

In the RNA interference process, the catalytic degradation of an endogenous mRNA results from the Watson-Crick complementary recognition by either a small silencing synthetic double-stranded ribonucleotide (siRNA) or by a small hairpin RNA (shRNA) produced in the cell by transcription from a DNA template. This interference process ideally results in an exquisitely specific mRNA suppression. The present review is dedicated to siRNAs. It describes the mechanism of RNA silencing and the main siRNA delivery techniques, with a focus on siRNA self-complexing to cationic lipids to form nanoparticles, which are called lipoplexes. The addition to lipoplexes of an anionic polymer leads to the ternary formulation APIRL (Anionic-Polymer-Interfering-RNA-Lipoplexes) with increased in vivo stability and biological efficacy. In terms of clinical development, the review focuses on therapeutic applications by intravenous delivery to the liver and inflammatory joints, and to localized siRNA delivery to the ocular sphere.
Not file

Dates and versions

hal-03292055 , version 1 (20-07-2021)

Identifiers

Cite

D. Scherman, A. Rousseau, P. Bigey, V. Escriou. Genetic pharmacology: progresses in siRNA delivery and therapeutic applications. Gene Therapy, 2017, 24 (3), pp.151-156. ⟨10.1038/gt.2017.6⟩. ⟨hal-03292055⟩
13 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More